Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02286557 · ClinicalTrials.gov registry record · Phase 2
Testing the Effects of Methylphenidate on Multiple Sclerosis
A Phase 2 study, sponsored by Kessler Foundation.
- Completed
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
NCT02286557 is a Phase 2 study that has completed, run by Kessler Foundation. The registered enrollment target is 36 participants.
The verdict
NCT02286557, a Phase 2 study, has completed, sponsored by Kessler Foundation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
Study Summary
Up to 95% of individuals with Multiple Sclerosis report experiencing cognitive fatigue, characterized by a lack of energy, feelings of exhaustion, an the perception that one is unable to partake in daily activities. The goal of this project is to test whether methylphenidate (MP), a well-known psychostimulant, can effective treat fatigue experienced by individuals with MS. The current study will test the effect of MP on MS fatigue through a clinical trial. Every participant in the study will be exposed to both the drug and the placebo for a period of time. Both the investigators and participants will be unaware whether participants are receiving the drug or the placebo. Upon successful completion of the study, physicians will be able to evaluate the potential prescription of MP to treat fatigue in persons with MS based on solid research evidence. Importantly, MP is already an FDA approved widely used medication in multiple clinical populations.
Interventions
- DRUG Placebo
- DRUG Methelphenidate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2014-10 |
| Est. Completion | 2025-03-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02286557
The ClinicalTrials.gov registry entry for NCT02286557 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kessler Foundation, which has 104 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02286557 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02286557 about?
NCT02286557 is a clinical study titled "Testing the Effects of Methylphenidate on Multiple Sclerosis". Up to 95% of individuals with Multiple Sclerosis report experiencing cognitive fatigue, characterized by a lack of energy, feelings of exhaustion, an the perception that one is unable to partake in daily activities. The goal of this project is to test whether methylphenidate (MP), a well-known psych...
What is the current status of trial NCT02286557?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2014-10. Estimated completion is 2025-03-04.
What interventions are being tested in trial NCT02286557?
The interventions under investigation include: Placebo (DRUG), Methelphenidate (DRUG).
Who is sponsoring clinical trial NCT02286557?
This trial is sponsored by Kessler Foundation, which has 104 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.